GitanjaliSrivastavaMD
Endocrinology • Nashville, TNObesity
Associate Professor of Medicine, Pediatrics & Surgery|Medical Director- Obesity Medicine|Program Director-Fellowship in Obesity Medicine, Vanderbilt
Dr. Srivastava is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3601 21st Ave S
Nashville, TN 37232Phone+1 615-936-2000Fax+1 615-322-4657
Education & Training
Icahn School of Medicine at Mount SinaiResidency, Internal Medicine/Pediatrics, 2003 - 2007
Louisiana State University School of Medicine in New OrleansClass of 2003
Certifications & Licensure
NH State Medical License 2008 - Present
TN State Medical License 2019 - 2026
LA State Medical License 2007 - 2025
AL State Medical License 2020 - 2020
MA State Medical License 2016 - 2019
FL State Medical License 2013 - 2018
NY State Medical License 2004 - 2009- American Board of Internal Medicine Internal Medicine
- American Board of Pediatrics Pediatrics
- American Board of Obesity Medicine Obesity Medicine
Publications & Presentations
PubMed
- 220 citationsCurrent pharmacotherapy for obesity.Gitanjali Srivastava, Caroline M. Apovian
Nature Reviews. Endocrinology. 2018-01-01 - 73 citationsTirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial.Thomas A Wadden, Ariana M Chao, Sriram Machineni, Robert Kushner, Jamy Ard
Nature Medicine. 2023-11-01 - 85 citationsClinical Considerations Regarding the Use of Obesity Pharmacotherapy in Adolescents with ObesityGitanjali Srivastava, Claudia K. Fox, Aaron S. Kelly, Ania M. Jastreboff, Allen Browne
Obesity. 2019-02-01
Press Mentions
As Obesity Booms, Doctors Seek Additional Treatment OptionsOctober 2nd, 2024- Doctors Seek Additional Obesity Training in Wake of Obesity Patient BoomOctober 1st, 2024
- Semaglutides like Ozempic Linked to Lower Opioid Overdose RiskSeptember 28th, 2024
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
